Department of Molecular Genetics, Cardiovascular Research Institute Maastricht, Maastricht University, Universiteitssingel 50, 6200 Maastricht, the Netherlands.
Arterioscler Thromb Vasc Biol. 2010 Nov;30(11):2188-95. doi: 10.1161/ATVBAHA.110.213124. Epub 2010 Sep 2.
To elucidate the downstream mechanisms of vascular endothelial growth factor receptor 2 (VEGFR2), a key receptor in angiogenesis, which has been associated with atherosclerotic plaque growth and instability.
By using a yeast-2-hybrid assay, we identified A Disintegrin And Metalloprotease 10 (ADAM10) as a novel binding partner of VEGFR2. ADAM10 is a metalloprotease with sheddase activity involved in cell migration; however, its exact function in endothelial cells (ECs), angiogenesis, and atherosclerosis is largely unknown. For the first time to our knowledge, we show ADAM10 expression in human atherosclerotic lesions, associated with plaque progression and neovascularization. We demonstrate ADAM10 expression and activity in ECs to be induced by VEGF; also, ADAM10 mediates the ectodomain shedding of VEGFR2. Furthermore, VEGF induces ADAM10-mediated cleavage of vascular endothelium (VE)-cadherin, which could increase vascular permeability and facilitate EC migration. Indeed, VEGF increases vascular permeability in an ADAM10- and ADAM17-dependent way; inhibition of ADAM10 reduces EC migration and chemotaxis.
These data provide the first evidence of ADAM10 expression in atherosclerosis and neovascularization. ADAM10 plays a functional role in VEGF-induced EC function. These data open perspectives for novel therapeutic interventions in vascular diseases.
阐明血管内皮生长因子受体 2(VEGFR2)的下游机制。VEGFR2 是血管生成中的关键受体,与动脉粥样硬化斑块的生长和不稳定性有关。
通过酵母双杂交试验,我们鉴定出 A 型血小板溶素和金属蛋白酶 10(ADAM10)是 VEGFR2 的一种新型结合伴侣。ADAM10 是一种具有解聚酶活性的金属蛋白酶,参与细胞迁移;然而,其在血管内皮细胞(EC)、血管生成和动脉粥样硬化中的确切功能在很大程度上尚不清楚。据我们所知,这是首次表明 ADAM10 在人类动脉粥样硬化病变中的表达与斑块进展和新生血管形成有关。我们证明 ADAM10 在 EC 中的表达和活性可被 VEGF 诱导;此外,ADAM10 介导 VEGFR2 的外显子脱落。此外,VEGF 诱导 ADAM10 介导的血管内皮钙黏蛋白(VE-钙黏蛋白)的裂解,这可能增加血管通透性并促进 EC 迁移。事实上,VEGF 以依赖 ADAM10 和 ADAM17 的方式增加血管通透性;抑制 ADAM10 可减少 EC 迁移和趋化性。
这些数据首次提供了 ADAM10 在动脉粥样硬化和新生血管形成中表达的证据。ADAM10 在 VEGF 诱导的 EC 功能中发挥功能作用。这些数据为血管疾病的新型治疗干预开辟了前景。